Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis

[1] Astor B. C.(2001)Timing of nephrologist referral and arteriovenous access use: the CHOICE Study American Journal of Kidney Diseases 38 494-501

[2] Eustace J. A.(2000)Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease Seminars in Dialysis 13 320-326

[3] Powe N. R.(2002)Effects of clinical and individual variables on quality of life in chronic renal failure patients Journal of Nephrology 15 61-67

[4] Klag M. J.(2005)Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Seminars in Dialysis 18 22-29

[5] Sadler J. H.(1998)The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin New England Journal of Medicine 339 584-590

[6] Fink N. E.(2005)Functional ability of patients on dialysis: the critical role of anemia Nephrology Nursing Journal 32 79-82

[7] Coresh J.(1998)Trends in anemia treatment with erythropoietin usage and patient outcomes American Journal of Kidney Diseases 32 S133-S141

[8] Athienites N. V.(1993)Second-generation logarithmic estimates of single-pool variable volume of Kt/V: an analysis of error Journal of the American Society of Nephrology 4 1204-1213

[9] Miskulin D. C.(1993)Erythropoietin is not a cause of access thrombosis Seminars in Dialysis 6 180-184

[10] Fernandez G.(1990)The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group The Journal of the American Medical Association 263 825-830

[1] Astor B. C.(2001)Timing of nephrologist referral and arteriovenous access use: the CHOICE Study American Journal of Kidney Diseases 38 494-501

[2] Eustace J. A.(2000)Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease Seminars in Dialysis 13 320-326

[3] Powe N. R.(2002)Effects of clinical and individual variables on quality of life in chronic renal failure patients Journal of Nephrology 15 61-67

[4] Klag M. J.(2005)Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Seminars in Dialysis 18 22-29

[5] Sadler J. H.(1998)The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin New England Journal of Medicine 339 584-590

[6] Fink N. E.(2005)Functional ability of patients on dialysis: the critical role of anemia Nephrology Nursing Journal 32 79-82

[7] Coresh J.(1998)Trends in anemia treatment with erythropoietin usage and patient outcomes American Journal of Kidney Diseases 32 S133-S141

[8] Athienites N. V.(1993)Second-generation logarithmic estimates of single-pool variable volume of Kt/V: an analysis of error Journal of the American Society of Nephrology 4 1204-1213

[9] Miskulin D. C.(1993)Erythropoietin is not a cause of access thrombosis Seminars in Dialysis 6 180-184

[10] Fernandez G.(1990)The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group The Journal of the American Medical Association 263 825-830